Claims for Patent: 10,335,462
✉ Email this page to a colleague
Summary for Patent: 10,335,462
| Title: | Use of long-acting GLP-1 peptides |
| Abstract: | The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc. |
| Inventor(s): | Jensen; Christine Bjoern (Charlottenlund, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 15/656,042 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,335,462 |
| Patent Claims: |
1. A method for treating type 2 diabetes, comprising administering semaglutide once weekly in an amount of 1.0 mg to a subject in need thereof.
2. The method according to claim 1, wherein the semaglutide is administered by parenteral administration. 3. The method according to claim 2, wherein the solution is administered by subcutaneous injection. 4. The method according to claim 1, wherein the semaglutide is administered in the form of an isotonic aqueous solution comprising phosphate buffer at a pH in the range of 7.0-9.0. 5. The method according to claim 4, wherein the solution further comprises propylene glycol and phenol. 6. The method according to claim 4, wherein the pH is 7.4. 7. The method according to claim 6, wherein the solution further comprises propylene glycol and phenol. 8. The method according to claim 4, wherein the phosphate buffer is a sodium dihydrogen phosphate buffer. 9. The method according to claim 1, wherein the semaglutide is administered by subcutaneous injection in the form of an isotonic aqueous solution comprising at a sodium dihydrogen phosphate buffer at a pH in the range of 7.0-9.0, and wherein the solution further comprises propylene glycol and phenol. 10. The method according to claim 9, wherein the pH is 7.4. |
